Adjunctive therapy in type 1 diabetes — evidence across compounds
Every compound the Institute assesses in adjunctive therapy in type 1 diabetes, with its certainty rating.
§2Evidence across compounds
Every compound the Institute assesses in this indication, with the effect as recorded, the certainty rating and the contributing trials. Effects are reported on the anchor outcome where the contributing trials measured it and on the outcome the trial actually reported where they did not.
Table 1. Compounds assessed in adjunctive therapy in type 1 diabetes, ordered by certainty.
| Compound | Effect as recorded | Interval as reported | Certainty | Trials |
|---|---|---|---|---|
| LiraglutideGLP-1 receptor agonist (acylated, once-daily) | HbA1c reduction of approximately 0.2 % with increased hypoglycaemia and hyperketonaemia | small effect, adverse safety trade-off | Moderate | 2 |
| PramlintideAmylin analogue, short-acting | HbA1c reduction of approximately 0.3 % with weight reduction of 1.4 kg and reduced insulin requirement | estimated HbA1c difference −0.3 % (95 % CI −0.4 to −0.2) | Moderate | 1 |
| Estimates in this table are not on a common scale and must not be subtracted from one another. Where a comparison between two compounds has been made directly, it appears in a synthesis and not here. | ||||
§2.1Syntheses bearing on this indication
- Liraglutide in adjunctive therapy in type 1 diabetes: effect on the anchor outcome — Moderate
- Liraglutide in adjunctive therapy in type 1 diabetes: tolerability and discontinuation — Moderate
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, Lau DCW, le Roux CW, Violante Ortiz R, Jensen CB, Wilding JPH. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine 2015;373(1):11–22. doi:10.1056/NEJMoa1411892 · PMID 26132939
- Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB. Liraglutide and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine 2016;375(4):311–322. doi:10.1056/NEJMoa1603827 · PMID 27295427
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.